Compare BCTX & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCTX | FLNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 30.0M |
| IPO Year | 2025 | 2000 |
| Metric | BCTX | FLNA |
|---|---|---|
| Price | $3.57 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 52.8K | ★ 319.1K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $250.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $0.56 |
| 52 Week High | $13.09 | $2.03 |
| Indicator | BCTX | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 25.93 |
| Support Level | $3.35 | N/A |
| Resistance Level | $3.74 | $0.68 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 56.94 | 1.85 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.